203 related articles for article (PubMed ID: 25254640)
1. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
2. Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.
Schuler AD; Engles CA; Maeda DY; Quinn MT; Kirpotina LN; Wicomb WN; Mason SN; Auten RL; Zebala JA
Bioorg Med Chem Lett; 2015 Sep; 25(18):3793-7. PubMed ID: 26248802
[TBL] [Abstract][Full Text] [Related]
3. Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Auten RL; Gundla R; Zebala JA
Bioorg Med Chem Lett; 2015 Jun; 25(11):2280-4. PubMed ID: 25933594
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
5. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.
Maeda DY; Quinn MT; Schepetkin IA; Kirpotina LN; Zebala JA
J Pharmacol Exp Ther; 2010 Jan; 332(1):145-52. PubMed ID: 19779130
[TBL] [Abstract][Full Text] [Related]
7. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
8. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions.
Raghuwanshi SK; Su Y; Singh V; Haynes K; Richmond A; Richardson RM
J Immunol; 2012 Sep; 189(6):2824-32. PubMed ID: 22869904
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
Kaur M; Singh D
J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
[TBL] [Abstract][Full Text] [Related]
10. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
Cunha TM; Barsante MM; Guerrero AT; Verri WA; Ferreira SH; Coelho FM; Bertini R; Di Giacinto C; Allegretti M; Cunha FQ; Teixeira MM
Br J Pharmacol; 2008 May; 154(2):460-70. PubMed ID: 18362895
[TBL] [Abstract][Full Text] [Related]
11. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
12. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
Russo RC; Garcia CC; Teixeira MM; Amaral FA
Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
[TBL] [Abstract][Full Text] [Related]
13. Fine-Tuning of GPCR-Chemokine Interactions. Design and Identification of Chemokine Analogues as Receptor Agonists, Biased Agonists, and Antagonists.
Navarro J
Biochemistry; 2019 Mar; 58(10):1432-1439. PubMed ID: 30726064
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
15. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology.
Zhao X; Li F; Town JR; Zhang X; Wang W; Gordon JR
Int Immunopharmacol; 2007 Dec; 7(13):1723-31. PubMed ID: 17996682
[TBL] [Abstract][Full Text] [Related]
16. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2.
de Kruijf P; Lim HD; Overbeek SA; Zaman GJ; Kraneveld AD; Folkerts G; Leurs R; Smit MJ
Eur J Pharmacol; 2010 Sep; 643(1):29-33. PubMed ID: 20599927
[TBL] [Abstract][Full Text] [Related]
17. Actin filaments are involved in the regulation of trafficking of two closely related chemokine receptors, CXCR1 and CXCR2.
Zaslaver A; Feniger-Barish R; Ben-Baruch A
J Immunol; 2001 Jan; 166(2):1272-84. PubMed ID: 11145710
[TBL] [Abstract][Full Text] [Related]
18. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.
Schraufstatter IU; Chung J; Burger M
Am J Physiol Lung Cell Mol Physiol; 2001 Jun; 280(6):L1094-103. PubMed ID: 11350788
[TBL] [Abstract][Full Text] [Related]
19. CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization.
Nasser MW; Raghuwanshi SK; Malloy KM; Gangavarapu P; Shim JY; Rajarathnam K; Richardson RM
J Biol Chem; 2007 Mar; 282(9):6906-15. PubMed ID: 17204468
[TBL] [Abstract][Full Text] [Related]
20. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
